“Oncological resectability” emphasizes achieving durable disease control, integrating factors such as tumor biology (RAS/BRAF mutation status, response to systemic therapy) and patient’s general condition into surgical decision-making [123,124]. This evidence concerns the gene BRAF and neoplasm.